Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03363841 · ClinicalTrials.gov registry record · Phase 3
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
A Phase 3 study, sponsored by Scynexis.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT03363841 is a Phase 3 study that has completed, run by Scynexis. The registered enrollment target is 30 participants.
The verdict
NCT03363841, a Phase 3 study, has completed, sponsored by Scynexis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, non-comparator, single-arm study to evaluate the efficacy, safety, tolerability and PK (pharmacokinetics) of oral SCY-078 as an emergency use treatment for patients with a documented Candida auris infection.
Interventions
- DRUG SCY-078
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2023-05-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03363841
The ClinicalTrials.gov registry entry for NCT03363841 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scynexis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SCY-078 is the first listed.
NCT03363841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03363841 about?
NCT03363841 is a clinical study titled "Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)". This is a multicenter, open-label, non-comparator, single-arm study to evaluate the efficacy, safety, tolerability and PK (pharmacokinetics) of oral SCY-078 as an emergency use treatment for patients with a documented Candida auris infection.
What is the current status of trial NCT03363841?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2017-11-15. Estimated completion is 2023-05-24.
What interventions are being tested in trial NCT03363841?
The interventions under investigation include: SCY-078 (DRUG).
Who is sponsoring clinical trial NCT03363841?
This trial is sponsored by Scynexis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.